Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 19

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 19
---
 clinical efforts, conducting research, furthering development, continuing current and future pre-clinical and clinical trials and,
eventually, commercialization of our novel therapeutics technology will involve substantial costs. If we obtain regulatory approval for
any of our product candidates, we expect to incur additional significant commercialization expenses related to regulatory requirements,
product manufacturing, marketing, sales and distribution.

Furthermore, we expect to incur additional costs
associated with operating as an SEC reporting public company. We may also encounter unforeseen expenses, difficulties, complications,
delays and other unknown factors that may increase our capital needs and/or cause us to spend our cash resources faster than we expect.

Until we can generate a sufficient amount of
product revenue to finance our cash requirements, which we may never achieve, we expect to finance our cash needs primarily through public
or private equity offerings, debt financings or through the establishment of possible strategic alliances.

Between 2020 and 2023, we raised aggregate gross
proceeds of $8.15 million, from sales of our equity and equity linked securities. Nonetheless, we will need to obtain substantial additional
funding for the further development and commercialization of our product candidates and to continue our operations. The actual amount
of funds that we will need will be determined by many factors, some of which are beyond our control. These factors include:

| ● | The progress and breadth                                                                                                              
 of pre-clinical testing and the size or complexity of our clinical trials and drug delivery programs, all of which directly influence 
 cost;                                                                                                                                 |

| ● | Higher than expected costs                                                                                                       
 involved in complying with the regulatory process to get our drug candidates approved, including the number, size, and timing of 
 necessary clinical trials and costs and review of existing clinical and pre-clinical information;                                |

| ● | Higher than expected costs                                                                                         
 involved in patenting our technologies and defending them and pursuing our overall intellectual property strategy. |

<div align='center'>8</div>

| ● | Changes in our existing                                                                                                          
 research and development relationships and our ability to efficiently negotiate and enter into new collaboration and partnership 
 agreements;                                                                                                                      |

| ● | Our ability to establish                                                                                                            
 and maintain current and new research and development and licensing arrangements and terminations of our existing collaboration and 
 licensing arrangements.                                                                                                             |

| ● | Faster or slower than expected                                                                                        
 rate of progress and changes in the scope and the cost of our research and development and clinical trial activities. |

| ● | Higher than expected costs